Anthony V. D'Amico
Created the low, intermediate and high-risk classification that every prostate cancer decision starts from.
Overview
Anthony D'Amico developed the 1998 risk stratification of localised prostate cancer by PSA, Gleason score and stage that remains the backbone of guidelines and trial eligibility, and led the randomised trial showing six months of androgen deprivation with radiotherapy improves survival in intermediate and high-risk disease. He continues to publish on PSA kinetics and on tailoring hormone therapy duration.
Pages like this
not linked directly; found by shared links- PersonAnthony L. Zietman
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags prostate, radiotherapy.
- PersonDaniel E. Spratt
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags prostate, radiotherapy.
- PersonMatthew R. Smith
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
- PersonChristopher J. Sweeney
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
- PersonAndrew J. Armstrong
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
- IdeaUse food effects to cut the dose and cost of oral drugs that absorb better with meals
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
- PairingAI pathology → androgen deprivation duration
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
- PersonA. Murray Brunt
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.